Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Maud Reymond"'
Autor:
Anthony Buisson, Lysa Blanco, Luc Manlay, Maud Reymond, Michel Dapoigny, Olivier Rouquette, Anne Dubois, Bruno Pereira
Publikováno v:
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 2022, ⟨10.1093/ibd/izac065⟩
Inflammatory Bowel Diseases, 2022, ⟨10.1093/ibd/izac065⟩
Background The best management after ileocolonic resection is still unknown in Crohn’s disease (CD). We compared step-up and top-down approaches to prevent short and long-term postoperative recurrences in CD patients. Methods From a comprehensive d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a4ebb8f8de075f03c4dca785889048
https://doi.org/10.1093/ibd/izac065
https://doi.org/10.1093/ibd/izac065
Autor:
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fumery
Publikováno v:
Clinical Gastroenterology and Hepatology.
We assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with or without intensified intravenous regimen.In this multicenter observational study, IBD patients i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::612c4c95a1341293054ebcdeaed79767
https://doi.org/10.1016/j.cgh.2022.08.011
https://doi.org/10.1016/j.cgh.2022.08.011
Autor:
Michel Dapoigny, Constance Hordonneau, Felix Goutorbe, Guillaume Bouguen, A.-L. Boucher, M. Goutte, Jean-Marie Reimund, Maud Reymond, Gilles Bommelaer, Julien Scanzi, C. Allimant, L Messadeg, Bruno Pereira, Anthony Buisson
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2020, 14 (11), pp.1524-1534. ⟨10.1093/ecco-jcc/jjaa098⟩
Journal of Crohn's and Colitis, 2020, 14 (11), pp.1524-1534. ⟨10.1093/ecco-jcc/jjaa098⟩
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2020, 14 (11), pp.1524-1534. ⟨10.1093/ecco-jcc/jjaa098⟩
Journal of Crohn's and Colitis, 2020, 14 (11), pp.1524-1534. ⟨10.1093/ecco-jcc/jjaa098⟩
Background Magnetic resonance imaging [MRI] is a promising tool to evaluate therapeutic efficacy in ileocolonic Crohn’s disease [CD]. Aims We aimed to assess the feasibility of early MRI evaluation (week 12 [W12]) to predict corticosteroid-free rem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c50079c0c4279c7f39dbed97c25bb5d
https://doi.org/10.1093/ecco-jcc/jjaa098
https://doi.org/10.1093/ecco-jcc/jjaa098
Autor:
Vered Abitbol, Stephanie Viennot, Catherine Reenaers, Jean-Marie Reimund, Lucine Vuitton, Mélanie Serrero, Philippe Seksik, Jérôme Filippi, Mathurin Fumery, Guillaume Savoye, David Laharie, Bénédicte Caron, Caroline Trang-Poisson, Jean-Pierre Bronowicki, Guillaume Bouguen, Benjamin Pariente, Maud Reymond, Laurent Peyrin-Biroulet, Stéphane Nancey, Romain Altwegg, L Caillo, Franck Carbonnel, Yoram Bouhnik, Aurelien Amiot
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2019, 13 (10), pp.1239-1247. ⟨10.1093/ecco-jcc/jjz088⟩
Journal of Crohn's and Colitis, 2019, 13 (10), pp.1239-1247. ⟨10.1093/ecco-jcc/jjz088⟩
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2019, 13 (10), pp.1239-1247. ⟨10.1093/ecco-jcc/jjz088⟩
Journal of Crohn's and Colitis, 2019, 13 (10), pp.1239-1247. ⟨10.1093/ecco-jcc/jjz088⟩
Background Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis [PSC] in patients with inflammatory bowel disease [IBD] remains controversial. Methods We performed a retrospective observational study of consecutive p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb8f28d932c2f4fd626f2ef7b2c574e
https://doi.org/10.1093/ecco-jcc/jjz088
https://doi.org/10.1093/ecco-jcc/jjz088
Autor:
Estelle Rebillard, Benjamin Buchard, Nicolas De Abreu, Mathieu Boulin, Anne Minello Franza, Benoît Magnin, Maud Reymond, Leon Muti, Bruno Pereira, Armand Abergel
Publikováno v:
Journal of Hepatology. 77:S918
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86fb8404681e7a82d68a3ae11872d83b
https://doi.org/10.1016/s0168-8278(22)02120-1
https://doi.org/10.1016/s0168-8278(22)02120-1
Autor:
Luc Manlay, Gilles Boschetti, Bruno Pereira, Bernard Flourié, Michel Dapoigny, Maud Reymond, Elisa Sollelis, Claire Gay, Mathilde Boube, Anthony Buisson, Stéphane Nancey
Publikováno v:
Alimentary Pharmacology & Therapeutics (Suppl)
Alimentary Pharmacology & Therapeutics (Suppl), 2021, 53 (12), pp.1289-1299. ⟨10.1111/apt.16377⟩
Alimentary Pharmacology & Therapeutics (Suppl), 2021, 53 (12), pp.1289-1299. ⟨10.1111/apt.16377⟩
International audience; Background The best option between vedolizumab and ustekinumab after anti-tumour necrosis factor (TNF) failure remains unclear in Crohn's disease.Aims To compare the short- and long-term effectiveness of vedolizumab and usteki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2652049eb780af3af66c93ab6ce48e7
https://pubmed.ncbi.nlm.nih.gov/34170547
https://pubmed.ncbi.nlm.nih.gov/34170547
Autor:
Anthony Buisson, Lysa Blanco, Luc Manlay, Maud Reymond, Michel Dapoigny, Olivier Rouquette, Anne Dubois, Bruno Pereira
Publikováno v:
Gastroenterology. 162:S-604
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c6e68fad3f75b5c6c579192bb595ee6
https://doi.org/10.1016/s0016-5085(22)61426-4
https://doi.org/10.1016/s0016-5085(22)61426-4
Autor:
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Luc Manlay, Bruno Pereira, Mathurin Fumery
Publikováno v:
Gastroenterology. 162:S-182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6be358921ca64a20dabccf57e809761a
https://doi.org/10.1016/s0016-5085(22)60437-2
https://doi.org/10.1016/s0016-5085(22)60437-2
Autor:
Véronique Loustaud-Ratti, Armand Abergel, Nicolas Andant, A. Mallat, Marie Dodel, Isabelle Fouchard-Hubert, Stanislas Pol, Maud Reymond, Brigitte Chanteranne, Bruno Pereira, François Bailly, Dominique Larrey, Albert Tran, Didier Samuel, Frederic Faure, Vincent Di Martino, J. Gournay, Benjamin Buchard, Tarik Asselah, Géraldine Lamblin, Leon Muti, Camille Teilhet
Publikováno v:
Liver International
Liver International, Wiley-Blackwell, 2020, 40 (8), pp.1853-1859. ⟨10.1111/liv.14502⟩
Liver International, Wiley-Blackwell, 2020, 40 (8), pp.1853-1859. ⟨10.1111/liv.14502⟩
BACKGROUND Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788a274f99cb0b65221011f050bb1e22
https://hal.univ-angers.fr/hal-03287285
https://hal.univ-angers.fr/hal-03287285
Autor:
Brigitte Chanteranne, Frederic Faure, Stanislas Pol, J. Gournay, Leon Muti, Armand Abergel, Géraldine Lamblin, Isabelle Fouchard-Hubert, Maud Reymond, Camille Teilhet, Benjamin Buchard, Véronique Loustaud-Ratti, A. Mallat, Marie Dodel, Bruno Pereira, Dominique Larrey, Nicolas Andant, Didier Samuel, Vincent Di Martino, Tarik Asselah, Albert Tran, François Bailly
Publikováno v:
SSRN Electronic Journal.
Background: Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accord
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ab76b6071f8f357af85e49282cea21e
https://doi.org/10.2139/ssrn.3522580
https://doi.org/10.2139/ssrn.3522580